BioCryst Pharmaceuticals announced this week that the APeX-1 clinical trial involving BCX7353, which is designed to treat hereditary angioedema (HAE), has begun with the first patient being dosed. Read More »
SANUWAVE Health Inc. announced today that a de novo petition has been submitted to the U.S. Food and Drug Administration (FDA) asking for the review and classification of the dermaPACE System to be used in the treatment of Diabetic Foot Ulcers (DFU) as a Class II device. Read More »
WASHINGTON, D.C. -- Medicare Part D premiums will see only a modest rise in 2017, despite costs to taxpayers growing faster than parts A and B, the Centers for Medicare and Medicaid Services (CMS) recently said in a statement. Read More »
Avion Pharmaceuticals recently announced its support of August being designated National Breastfeeding Month by the U.S. Breastfeeding Committee (USBC). Read More »
Pfizer Inc. has announced that analysis of data from three studies involving VYNDAQEL have been published. Read More »
Walgreens recently announced that 45 of its locations in Illinois have installed drug take-back kiosks as part of the company’s safe medication disposal kiosk program, designed to provide a safe, convenient means for prescription disposal. Read More »
AstraZeneca recently released the results of the selumetinib, a MEK 1/2 inhibitor, Phase III SELECT-1 trial. Read More »
ImpediMed Limited, a provider of medical technology used to measure, monitor and manage the status of fluid and the composition of the body, recently reported that the U.S. Food and Drug Administration (FDA) has released new digital health guidance. Read More »
Coherus BioSciences has announced that it has submitted a biologics license application (BLA) for CHS-1701 to the U.S. Food and Drug Administration (FDA) under the pathway of 351(k). Read More »
Wellpartner, a leader in the provision of the 340B Drug Pricing Program and specialty pharmacy services, recently announced that it has begun providing covered entities with access to more than 60,000 independent, regional and national chain pharmacies. Read More »
Eaglet Corp. recently reported that two U.S. Food and Drug Administration (FDA) advisory committees voted to recommend the approval of ARYMO ER. Read More »
Proteostasis Therapeutics Inc. recently announced key leadership appointments. Read More »
.jpg)
The U.S. Food and Drug Administration (FDA) recently approved Merck’s anti-PD-1 therapy, KEYTRUDA, for use in fixed doses of 200 mg on a tri-weekly basis for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients. Read More »
Proteostasis Therapeutics Inc. recently announced the successful completion of an important preclinical goal in its partnerships with Astellas Pharma Inc. Read More »
A&D Medical, a worldwide leader in connecting health and biometric measurement devices and services, was on track to reveal its new PlusConnect Wireless Weight Scale at the National Association of Chain Drug Stores (NACDS) conference. Read More »
DigiTx Partners, a digital health investment firm, recently resulted from a three-way partnership between San Francisco’s DigiTx Partners LLC , Tokyo-based Astellas Pharma Inc. and Boston-based MPM Capital Inc. Read More »
Abbott has introduced its line of next-generation systems, call Alinity. Read More »
To expedite and encourage the growth of independent local pharmacies in an evolving health care atmosphere, the Alexandria, Virginia-based National Community Pharmacists Association (NCPA) recently launched a new Innovation Center designed for outreach and education. Read More »
Amgen and Advaxis has announced the finalization of a worldwide agreement for the development and commercialization of Advaxis’ ADXS-NEO, a novel, preclinical investigational immunotherapy developed for the treatment of cancer. Read More »
Aetna and Humana this week announced that the two companies have agreed to sell Medicare Advantage assets to Molina Healthcare, Inc. for approximately $117 million, which is based on the estimated number of members in the plans covered in the transactions. Read More »
Alerts Sign-up
